| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 4.6MM | -41% |
| Gross Profit | 2.7MM | -33% |
| Cost Of Revenue | 1.8MM | -51% |
| Operating Income | -5.3MM | -6% |
| Operating Expenses | 8MM | -17% |
| Net Income | -5MM | -6% |
| R&D | 2.2MM | -17% |
| G&A | 3MM | -23% |
| Marketing | 2.8MM | -10% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
ST. LOUIS, April 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2024 first quarter on Monday, May 13, 2024 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company’s results and corporate developments. What: Stereotaxis first quarter 2024 fin
Penny stocks could be your ticket to striking it rich. But don’t expect easy money! While these thinly traded sub-$5 stocks offer the tantalizing prospect of turning pocket change into a small fortune, finding the diamonds in the rough is easier said than done. This has led to this list of penny stocks to buy. For every penny stock that skyrockets, there are dozens that fizzle out and leave investors holding the bag. It takes a keen eye and a high-risk tolerance to separate the winners from the
Stereotaxis (STXS) announces the regulatory submissions of its MAGiC catheter in Europe and the United States, which are intended for use in minimally invasive cardiac ablation treatments.
Stereotaxis, Inc. (AMEX:STXS) Q4 2023 Earnings Call Transcript March 4, 2024 Stereotaxis, Inc. reports earnings inline with expectations. Reported EPS is $-0.07 EPS, expectations were $-0.07. STXS isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon. Thank you for […]
Q4 2023 Stereotaxis Inc Earnings Call
Full Year Earnings Report Highlights Challenges and Future Growth Opportunities
ST. LOUIS, March 04, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that regulatory submissions were made recently in both Europe and the United States for the MAGiC™ catheter. These submissions follow successful initial clinical results in an ongoing trial. Stereotaxis’ MAGiC catheter is a robotically navigated magnetic ablation catheter designed to perform minimally invasive c
ST. LOUIS, March 04, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2023. “We enter 2024 having made significant progress in realizing our strategic transformation. This is the year in which we expect all the key puzzle pieces to come together, setting us up for breakout growth to follow,” said David Fische
Alphatec (ATEC) delivered earnings and revenue surprises of -32.14% and 0.27%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Penumbra (PEN) delivered earnings and revenue surprises of 7.04% and 1%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?